Physician profile
Nancy Cheng
NPI 1073874178
$3,009.45
in general payments reported to CMS, 2019-2025
26 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $119 · 2021: $17.52 · 2022: $20.70 · 2023: $91.97 · 2024: $653 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.33 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $508.13 | 2022-2025 | |
| Janssen Biotech, INC. | $402.10 | 2024-2025 | Tremfya |
| Abbvie INC. | $359.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.92 | 2025 | Dupixent, Libtayo |
| Incyte Corporation | $168.41 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $146.46 | 2019-2025 | Sotyktu |
| Allergan, INC. | $111.45 | 2019 | |
| Genzyme Corporation | $107.06 | 2025 | |
| Janssen Scientific Affairs, LLC | $105.33 | 2020 | |
| Radius Health, INC. | $96.78 | 2019 | |
| Amgen INC. | $95.63 | 2023-2025 | Otezla, Otezla |
| Celgene Corporation | $91.00 | 2019 | |
| Ucb, INC. | $82.08 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $68.29 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $66.37 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $66.16 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $55.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.55 | 2024-2025 | Spevigo |
| Dusa Pharmaceuticals, INC. | $47.93 | 2019 | |
| Leo Pharma INC. | $47.38 | 2024-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $46.85 | 2024-2025 | Ycanth |
| Almirall LLC | $24.36 | 2024 | Klisyri |
| Lilly USA, LLC | $18.26 | 2024 | Ebglyss |
| Pierre Fabre Pharmaceuticals, INC. | $17.52 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.90 | 2025 | Valchlor |
| Dermavant Sciences, INC. | $13.43 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.